clinical trial · NCT06284902
Bioavailability Study of Fexofenadine HCl New Formulation Tablet
Opella Healthcare Group SAS, a Sanofi Company·phase1·completed·n = 25
Healthy VolunteersFexofenadine HCl Coated tabletFexofenadine HCl New Formulation Tablet
brief summary
The purpose of the study is to assess the relative bioavailability of a new galenic form of fexofenadine HCl new formulation tablet (test drug) taken with or without water compared to fexofenadine HCl film-coated tablets (reference form) taken with water under fasting conditions.
started
Feb 23, 2024
primary completion
May 8, 2024
completion
May 23, 2024
last updated
Sep 12, 2025
official title
Open-Label, Single-Dose, Randomized, 6-Treatment, 6-Sequence, 6-Period Crossover Relative Bioavailability Study Comparing Fexofenadine HCl New Formulation Tablets (Test Drug) With or Without Water to Fexofenadine HCl Coated Tablets (Reference Drug) With Water in Healthy Male and Female Subjects Under Fasting Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol